Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis and Metrics

Amphastar Pharmaceuticals

NASDAQ: AMPH

$18.72 ▼ -0.15 (-0.79%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap853.87 Mn

P/E8.34

P/S1.19

Div. Yield0.00

ROIC (Qtr)0.26

Total Debt (Qtr)611.47 Mn

Revenue Growth (1y) (Qtr)0.38

Add ratio to table…

About

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient (API) products.

The company generates revenue primarily through the sale of its generic and proprietary injectable, inhalation, and intranasal products, as well as API products, to hospitals, long-term care facilities, clinics, physicians' offices, and retail pharmacies. In the years ended December 31, 2025, 2024, and 2023, Amphastar recorded net revenues of $719.9 million, $732.0 million, and $644.4 million, respectively. Its largest products by net revenue include BAQSIMI® glucagon nasal powder, Primatene MIST®, glucagon, epinephrine, and lidocaine. The company also markets an over-the-counter product, Primatene MIST®, and manufactures and sells API products such as recombinant human insulin and porcine insulin API to third parties.

Amphastar maintains a competitive stance in the injectable and inhalation markets by leveraging its vertically integrated infrastructure, which includes internal API manufacturing capabilities and multiple production facilities across the United States, France, and China. Its advanced technical capabilities encompass complex molecule characterization, peptide and protein analysis and synthesis, immunogenicity testing, particle engineering, and sustained-release technology, enabling the development of products with high barriers to entry and limited competition. The company faces competition from firms such as Pfizer, BPI Labs, Lupin Pharmaceuticals, Viatris, Fresenius Kabi USA, Apotex Corp, American Regent Inc., Hikma Pharmaceuticals USA, Inc., Par Pharmaceuticals, Cipla USA Inc., Meitheal Pharmaceuticals, Dr. Reddy’s Laboratories, Inc., Xeris Pharmaceuticals, Medefil Inc., Accord Healthcare, and Teva Pharmaceutical USA Inc. Amphastar’s strategic focus on technically challenging products, combined with its ability to manufacture key starting materials and intermediates, supports its efforts to achieve higher margins and sustainable growth.

The company's customers include major distributors such as McKesson, which accounted for 24% of net revenues in 2025, Cencora at 22%, and Cardinal Health at 19%. In addition to these wholesale distributors, Amphastar sells directly to institutions including hospitals, long-term care facilities, alternate care sites, clinics, and physicians' offices, as well as to retail pharmacies nationwide. Its products are also distributed through group purchasing organizations and specialty distributors that serve the healthcare sector.

Investment Thesis

▲ Bull case

Amphastar Pharmaceuticals' successful launch of AMP007 (ipratropium bromide inhalation) in April 2026 represents a significant near-term catalyst that is underappreciated by the market, as the product faces no direct generic competition and leverages the company's vertically integrated capabilities in complex generics. The product's approval and rapid market entry demonstrate Amphastar's strength in navigating technically challenging regulatory pathways, which not only validates its R&D infrastructure but also positions it to capture meaningful market share in a segment with sustained demand due to the prevalence of chronic obstructive pulmonary disease. Management highlighted that AMP007 is expected to be a major growth driver for the year, and its early traction—despite only being on the market for about a month at the time of the call—supports the upward revision of full-year sales guidance to mid-single-digit to high-single-digit unit growth, a projection that may prove conservative given the absence of competitive threats and the product's differentiation as the first and only generic option available. This launch effectively de-risks near-term revenue expectations and provides a foundation for sustained performance beyond reliance on legacy products facing pricing pressures.
The company's advancement toward regulatory milestones for its insulin aspart biosimilar (AMP004) and GLP-1 ANDA program, both targeting commercial launch in 2027, reflects a strategic pivot toward higher-value, complex biologics that are being underestimated in their long-term impact. Although these programs are still pre-revenue, Amphastar emphasized progress toward BLA submission and highlighted the over $1 billion annual sales potential of the reference insulin aspart product, suggesting that even a modest capture of market share could significantly alter the company's revenue profile. Importantly, management noted the pursuit of interchangeability designation, which, if achieved, would enable automatic substitution at the pharmacy level and substantially accelerate adoption— a factor not yet priced into current valuations. The internal funding of these initiatives through strong cash flow from operations ($47.8 million in Q1 FY26) and avoidance of external dilution or partnerships underscores confidence in their viability and reduces financial risk, positioning Amphastar to benefit from outsized upside if regulatory timelines are met or exceeded.
Amphastar's strategic shift to increase domestic sales concentration—from approximately 80% to a projected 85% of total sales following the orderly withdrawal from select international markets—represents an underrecognized operational improvement that enhances margin stability and reduces exposure to volatile foreign pricing and regulatory environments. Management clarified that the international exit is not a sudden drop-off but a phased process extending into early next year, minimizing disruption while allowing the company to redirect focus and resources toward its core U.S. business, where branded products like Vaximi and Primatene Mist continue to demonstrate underlying demand growth (8% and 6.5% year-over-year unit volume increases, respectively). This geographic realignment, combined with efforts to eliminate duplicate 340B rebates through third-party validation, addresses persistent net price erosion in key products and supports a recovery in gross margins, which declined to 71% in Q1 FY26 due to product mix shifts but are poised to rebound as higher-margin domestic sales gain weight and pricing initiatives (like the 3% list price increase on Vaximi effective May 1) take effect.

Amphastar Pharmaceuticals' successful launch of AMP007 (ipratropium bromide inhalation) in April 2026 represents a significant near-term catalyst that is underappreciated by the market, as the product faces no direct generic competition and leverages the company's vertically integrated capabilities in complex generics. The product's approval and rapid market entry demonstrate Amphastar's strength in navigating technically challenging regulatory pathways, which not only validates its R&D infrastructure but also positions it to capture meaningful market share in a segment with sustained demand due to the prevalence of chronic obstructive pulmonary disease. Management highlighted that AMP007 is expected to be a major growth driver for the year, and its early traction—despite only being on the market for about a month at the time of the call—supports the upward revision of full-year sales guidance to mid-single-digit to high-single-digit unit growth, a projection that may prove conservative given the absence of competitive threats and the product's differentiation as the first and only generic option available. This launch effectively de-risks near-term revenue expectations and provides a foundation for sustained performance beyond reliance on legacy products facing pricing pressures.
The company's advancement toward regulatory milestones for its insulin aspart biosimilar (AMP004) and GLP-1 ANDA program, both targeting commercial launch in 2027, reflects a strategic pivot toward higher-value, complex biologics that are being underestimated in their long-term impact. Although these programs are still pre-revenue, Amphastar emphasized progress toward BLA submission and highlighted the over $1 billion annual sales potential of the reference insulin aspart product, suggesting that even a modest capture of market share could significantly alter the company's revenue profile. Importantly, management noted the pursuit of interchangeability designation, which, if achieved, would enable automatic substitution at the pharmacy level and substantially accelerate adoption— a factor not yet priced into current valuations. The internal funding of these initiatives through strong cash flow from operations ($47.8 million in Q1 FY26) and avoidance of external dilution or partnerships underscores confidence in their viability and reduces financial risk, positioning Amphastar to benefit from outsized upside if regulatory timelines are met or exceeded.
Amphastar's strategic shift to increase domestic sales concentration—from approximately 80% to a projected 85% of total sales following the orderly withdrawal from select international markets—represents an underrecognized operational improvement that enhances margin stability and reduces exposure to volatile foreign pricing and regulatory environments. Management clarified that the international exit is not a sudden drop-off but a phased process extending into early next year, minimizing disruption while allowing the company to redirect focus and resources toward its core U.S. business, where branded products like Vaximi and Primatene Mist continue to demonstrate underlying demand growth (8% and 6.5% year-over-year unit volume increases, respectively). This geographic realignment, combined with efforts to eliminate duplicate 340B rebates through third-party validation, addresses persistent net price erosion in key products and supports a recovery in gross margins, which declined to 71% in Q1 FY26 due to product mix shifts but are poised to rebound as higher-margin domestic sales gain weight and pricing initiatives (like the 3% list price increase on Vaximi effective May 1) take effect.

▼ Bear case

Amphastar Pharmaceuticals faces persistent and underappreciated pressure on its legacy portfolio, particularly with Baqsimi (glucagon), where Q1 FY26 sales declined 56% year-over-year due to intensified competition and a market shift toward ready-to-use formulations—a structural trend that management acknowledged has not yet bottomed, despite noting a slowing rate of decline. The company's reliance on cost-cutting and operational efficiency to offset these losses may prove insufficient over time, as the erosion of high-margin products like Baqsimi, epinephrine multidose vials, and pythonodion directly contributed to the drop in gross margin to 71% in Q1 FY26 from 50% in the prior year, a figure that appears inconsistent with historical profitability and suggests deeper margin vulnerability than admitted. While management cited a 3% list price increase on Vaximi and efforts to resolve duplicate 340B rebates, these measures may not fully counteract the cumulative impact of rising rebates, channel shifts, and government program utilization that continue to suppress net pricing across key brands, raising doubts about the sustainability of mid-single-digit to high-single-digit growth guidance without meaningful contribution from unproven pipeline assets.
The advancement of Amphastar's pipeline, while promising, carries significant execution risk that the market may be underestimating, particularly regarding the insulin aspart biosimilar (AMP004) and GLP-1 ANDA programs, both targeting 2027 launches. Despite stating that AMP004 is "still in progress" with no changes to timeline, the company admitted it has not yet engaged the FDA on potential accelerated pathways, and regulatory alignment remains unconfirmed—a gap that introduces uncertainty around BLA submission timing and approval likelihood. Similarly, for the early-stage corticotropin program (product 110), management acknowledged no prior FDA meetings and no clarity on expedited development options, suggesting that preclinical and Phase 1 timelines could slip, delaying expected revenue contributions. Furthermore, the success of AMP004 hinges on securing interchangeability designation, which, if not achieved, would limit uptake to restrictive prescribing patterns and significantly reduce commercial potential in a crowded biosimilar market where incumbents like Eli Lilly and Novo Nordisk are aggressively defending share. The company’s reliance on internal funding, while financially prudent, also means that any clinical or regulatory setbacks would directly strain R&D capacity without the buffer of partner risk-sharing.
Although Amphastar highlighted the launch of AMP007 as a near-term growth driver, the company provided no concrete sales forecasts for the product, instead relying on qualitative statements about its potential to "outpace original assumptions," which introduces ambiguity about the near-term revenue contribution and its ability to offset declines in legacy segments. The lack of quantitative guidance, combined with the early stage of the product's commercialization (only one month on market at the time of the call), makes it difficult to assess whether AMP007 can meaningfully alleviate the drag from falling glucagon and epinephrine sales, especially if uptake is slower than anticipated due to formulary positioning, payer preferences, or delayed adoption by prescribers unfamiliar with the generic alternative. Additionally, while management emphasized the product's status as the first and only generic ipratropium inhaled option, this advantage may be transient if competitors accelerate their own approval timelines—a risk not addressed in the call—and could be undermined by potential shifts in treatment guidelines or increased utilization of nebulized alternatives in certain patient populations, limiting the long-term durability of this sales boost.

Amphastar Pharmaceuticals faces persistent and underappreciated pressure on its legacy portfolio, particularly with Baqsimi (glucagon), where Q1 FY26 sales declined 56% year-over-year due to intensified competition and a market shift toward ready-to-use formulations—a structural trend that management acknowledged has not yet bottomed, despite noting a slowing rate of decline. The company's reliance on cost-cutting and operational efficiency to offset these losses may prove insufficient over time, as the erosion of high-margin products like Baqsimi, epinephrine multidose vials, and pythonodion directly contributed to the drop in gross margin to 71% in Q1 FY26 from 50% in the prior year, a figure that appears inconsistent with historical profitability and suggests deeper margin vulnerability than admitted. While management cited a 3% list price increase on Vaximi and efforts to resolve duplicate 340B rebates, these measures may not fully counteract the cumulative impact of rising rebates, channel shifts, and government program utilization that continue to suppress net pricing across key brands, raising doubts about the sustainability of mid-single-digit to high-single-digit growth guidance without meaningful contribution from unproven pipeline assets.
The advancement of Amphastar's pipeline, while promising, carries significant execution risk that the market may be underestimating, particularly regarding the insulin aspart biosimilar (AMP004) and GLP-1 ANDA programs, both targeting 2027 launches. Despite stating that AMP004 is "still in progress" with no changes to timeline, the company admitted it has not yet engaged the FDA on potential accelerated pathways, and regulatory alignment remains unconfirmed—a gap that introduces uncertainty around BLA submission timing and approval likelihood. Similarly, for the early-stage corticotropin program (product 110), management acknowledged no prior FDA meetings and no clarity on expedited development options, suggesting that preclinical and Phase 1 timelines could slip, delaying expected revenue contributions. Furthermore, the success of AMP004 hinges on securing interchangeability designation, which, if not achieved, would limit uptake to restrictive prescribing patterns and significantly reduce commercial potential in a crowded biosimilar market where incumbents like Eli Lilly and Novo Nordisk are aggressively defending share. The company’s reliance on internal funding, while financially prudent, also means that any clinical or regulatory setbacks would directly strain R&D capacity without the buffer of partner risk-sharing.
Although Amphastar highlighted the launch of AMP007 as a near-term growth driver, the company provided no concrete sales forecasts for the product, instead relying on qualitative statements about its potential to "outpace original assumptions," which introduces ambiguity about the near-term revenue contribution and its ability to offset declines in legacy segments. The lack of quantitative guidance, combined with the early stage of the product's commercialization (only one month on market at the time of the call), makes it difficult to assess whether AMP007 can meaningfully alleviate the drag from falling glucagon and epinephrine sales, especially if uptake is slower than anticipated due to formulary positioning, payer preferences, or delayed adoption by prescribers unfamiliar with the generic alternative. Additionally, while management emphasized the product's status as the first and only generic ipratropium inhaled option, this advantage may be transient if competitors accelerate their own approval timelines—a risk not addressed in the call—and could be undermined by potential shifts in treatment guidelines or increased utilization of nebulized alternatives in certain patient populations, limiting the long-term durability of this sales boost.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Subsegments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Subsegments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password